Laquinimod
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].
Product Specifications
CAS Number
248281-84-7
Product Name Alternative
ABR-215062
UNSPSC
12352005
Hazard Statement
H301
Target
Apoptosis; NF-κB
Type
Reference compound
Related Pathways
Apoptosis; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Laquinimod.html
Purity
99.46
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2Cl)N(CC)C3=CC=CC=C3
Molecular Formula
C19H17ClN2O3
Molecular Weight
356.80
Precautions
H301
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
NF-κB
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Bis(perfluorohexyl)phosphinic Acid Sodium Salt
E-Cadherin (CDH1) / CD324 (Intercellular Junction Marker) (CDH1/3256), CF568 conjugate, 0.1mg/mL
VEGF Receptor 2 (KDR) pTyr1175 Rabbit Polyclonal Antibody
